Autoantibodies against p53, MMP-7, and Hsp70 as Potential Biomarkers for Detection of Nonmelanoma Skin Cancers

In this study, we assessed the diagnostic value of autoantibodies against p53, MMP-7, and Hsp70 in skin SCC and BCC. ELISA was performed to detect levels of autoantibodies in sera from 101 NMSC patients and 102 normal controls, who were recruited from the Cancer Hospital of Shantou University Medical College. A receiver operator characteristic curve was used to evaluate the diagnostic value. The serum levels of autoantibodies against p53, MMP-7, and Hsp70 were higher in NMSCs than those in the normal controls (all P
Source: Disease Markers - Category: Laboratory Medicine Authors: Source Type: research

Related Links:

Head and neck cutaneous squamous cell carcinoma (HNCSCC) is a non-melanoma skin cancer that is mostly caused by solar ultraviolet radiation exposure. While it usually has an excellent prognosis, a subset of pa...
Source: Journal of Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Authors: Tags: Review Source Type: research
AbstractNon-melanoma skin cancers include basal and squamous cell carcinoma. These tumors have become an important health issue for their high incidence and for the morbidity, especially if untreated for a long period. Over the last 20  years, therapeutic approaches for these tumours have been improved and tailored. In this survey we provided data from one hundred and ten Italian dermatologists regarding knowledge and attitude towards different therapeutic approaches on non-melanoma skin cancers. In our study, we observed that su rgery and imiquimod 5% cream were the most used treatment by dermatologists for basal cel...
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewThe therapeutic landscape for non-melanoma skin cancer (NMSC) has recently expanded with the development of effective and targeted immunotherapy. Here, we provide an overview of the role of immunotherapy in the management of advanced cutaneous carcinomas.Recent FindingsSeveral agents were recently U.S. Food and Drug Administration (FDA)-approved for the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma, Merkel cell carcinoma, and basal cell carcinoma. However, recent approvals in tissue-agnostic indications may also benefit other NMSCs including cutaneous adnexal solid ...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
Cutaneous squamous cell carcinoma (cSCC) is after basal cell carcinoma the second most common non-melanoma skin cancer (NMSC) with globally increasing incidence rates [1,2]. Complete excision under histopathological guidance is the standard treatment of cSCC [3] with a generally favourable outcome. However, a significant percentage of patients exhibit large primary tumors, recurrent or metastatic disease, whereby therapeutic options can be limited, in particular in view of patients' age or comorbidities.
Source: Journal of Dermatological Science - Category: Dermatology Authors: Source Type: research
Treatment of melanoma (MSC) and non-melanoma skin cancers (NMSCs, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC)), affecting one-fifth of the US population, is hampered by drug resistance, side effects, and low bioavailability. Owing to low molecular weight and the ability to enter cells, small molecules are gaining ground towards enhancing bioavailability and minimizing some of the side effects associated with classical cancer drugs. Herein, we synthesized a mini-library of 86 compounds via C-N/C-C coupling, direct substitution on the aromatic ring, or a modified Skraup –Doebner–von Miller appro...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Source Type: research
Postepy Dermatol Alergol. 2021 Apr;38(2):198-204. doi: 10.5114/ada.2021.106196. Epub 2021 May 22.ABSTRACTCutaneous squamous cell carcinoma represents the second most common non-melanoma skin cancer and its incidence increases worldwide. This review provides an overview of selected exogenous risk factors for cutaneous squamous cell carcinoma, which include drugs (azathioprine, calcineurin inhibitors, hydrochlorothiazide, angiotensin-converting-enzyme inhibitors) and few dietary factors (fat meet, whole milk products, arsenic) to better understand squamous skin cancer etiopathogenesis. Ingredients such as leafy vegetables, n...
Source: Advances in Dermatology and Allergology - Category: Dermatology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hospitals | Laboratory Medicine | Nonmelanoma Skin Cancer | Skin | Skin Cancer | Squamous Cell Carcinoma | Study